Italia Markets closed

Royalty Pharma plc (RPRX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
34,80-0,06 (-0,17%)
Alla chiusura: 04:00PM EDT
34,61 -0,19 (-0,53%)
Dopo ore: 05:28PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente34,86
Denaro34,57 x 1000
Lettera34,79 x 800
Min-Max giorno34,58 - 35,13
Intervallo di 52 settimane32,68 - 44,75
Media Volume1.833.538
Beta (5 anni mensile)0,39
Rapporto PE (ttm)18,07
EPS (ttm)1,93
Prossima data utili03 mag 2023 - 08 mag 2023
Rendimento e dividendo (forward)0,80 (2,10%)
Data ex dividendo15 feb 2023
Stima target 1A53,71
  • GlobeNewswire

    Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million

    Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholdsPureTech retains its current equity stake in Karuna in addition to milestone payments and 20% of sublicense revenues due to PureTechTransaction provides further non-dilutive capital for PureTech’s growing and rapidly advancing Wholly Owned Pipeline, with five clinical-stage candidates expected by the end of 2023 NEW

  • GlobeNewswire

    Royalty Pharma Raises Full Year 2023 Guidance

    Royalty Pharma now expects 2023 Adjusted Cash Receipts(1) (non-GAAP) to be between $2,850 million and $2,950 million, excluding contributions from future transactions NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has received a $475 million accelerated milestone payment from Pfizer, following the U.S. Food and Drug Administration (FDA) approval of Zavzpret (zavegepant), a calcitonin gene-related peptide (CGRP) receptor antagonist nasal spr

  • GlobeNewswire

    Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments

    NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Ashwin Pai, M.D. as Executive Vice President, Investments. Ashwin will join Royalty Pharma in April 2023, and will report to Chris Hite, Executive Vice President and Vice Chairman. Ashwin joins Royalty Pharma from Morgan Stanley where he was a Managing Director and Head of West Coast Biotechnology Investment Banking. In his nearly two decade career, Ashwin has been involved in some o